JPH07255845A - Jet injection percutaneous absorption device and precutaneous absorption promoting method - Google Patents

Jet injection percutaneous absorption device and precutaneous absorption promoting method

Info

Publication number
JPH07255845A
JPH07255845A JP6079342A JP7934294A JPH07255845A JP H07255845 A JPH07255845 A JP H07255845A JP 6079342 A JP6079342 A JP 6079342A JP 7934294 A JP7934294 A JP 7934294A JP H07255845 A JPH07255845 A JP H07255845A
Authority
JP
Japan
Prior art keywords
rubber
skin
reservoir
opening
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP6079342A
Other languages
Japanese (ja)
Other versions
JP3425469B2 (en
Inventor
Kazutoshi Morimoto
雍憲 森本
Kenji Sugibayashi
堅次 杉林
Masayuki Kimura
昌行 木村
Daisuke Kobayashi
大介 小林
Naoko Inoue
直子 井上
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toko Yakuhin Kogyo KK
Original Assignee
Toko Yakuhin Kogyo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toko Yakuhin Kogyo KK filed Critical Toko Yakuhin Kogyo KK
Priority to JP07934294A priority Critical patent/JP3425469B2/en
Publication of JPH07255845A publication Critical patent/JPH07255845A/en
Application granted granted Critical
Publication of JP3425469B2 publication Critical patent/JP3425469B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

PURPOSE:To provide a device excellent in persistence and gradually releasing performance by providing a medicine permeable pressure sensitive adhesive layer to block up an opening part of a bottom part of a box-shaped casing and rubber to block up an opening part of a ceiling part of the casing in the device to percutaneously absorb medicine-containing solution or the like by passing through the skin. CONSTITUTION:A box-shaped casing 1 having a circular hole in a ceiling part and an opening in a bottom part, is provided, and semispherical silicon rubber 2 becoming a downward projection is adhered to the periphery of the circular hole of the ceiling part, and the bottom part opening is blocked up by an acrylic pressure sensitive adhesive layer 3, and a reservoir 4 is constituted. A jet injector 5 is injected from above the silicon rubber 2 of this reservoir 4, and a hole is bored in a skin surface. At this time, when it is injected from above the rubber 2 of the reservoir 4, a small hole of the rubber 2 formed at solution injection time is instantly blocked up, and leakage of chemicals is prevented. Though a hole is also bored in the pressure sensitive adhesive layer 3 facing the skin, the hole is blocked up by the stickiness.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、ジェットインジェクシ
ョンの道具を用いて薬物を含む溶液等を皮膚透過させる
ことにより経皮吸収させる装置及び方法に関するもので
ある。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an apparatus and method for percutaneously absorbing a solution containing a drug or the like through the skin by using a jet injection tool.

【0002】[0002]

【従来技術】ジェットインジェクション法は、水圧を利
用して薬液を体内に送り込む無針注射方法で、カナダの
メディカルテクノロジー社において開発・製造され、日
本ではプレシジェット(小玉薬品工業株式会社の商品
名)を用いたインスリンの皮下注射に臨床応用されてい
る。
2. Description of the Related Art The jet injection method is a needleless injection method in which a drug solution is sent into the body by using water pressure. It was developed and manufactured by Medical Technology Company of Canada, and in Japan, Precijet (trade name of Kodama Pharmaceutical Co., Ltd.) It has been clinically applied to subcutaneous injection of insulin.

【0003】[0003]

【発明が解決しようとする課題】しかしながら、かかる
従来のジェットインジェクションによる薬剤投与方法
は、直接皮膚に穴をあけ薬液注入するものであるため、
即効性に優れるものの、持続性、除放性に不向きであ
る。そこで本発明は、かかる従来技術の欠点に鑑みなさ
れたもので、ジェットインジェクションを用い、持続性
及び徐放性に優れたジェットインジェクション経皮吸収
装置及びジェットインジェクション経皮吸収促進方法を
提供することを目的とする。さらに本発明は、薬物の経
皮吸収性あるいは皮膚移行性を上昇させ、経口投与不能
患者あるいは薬物の体内濃度を長期にわたり維持する必
要のある患者の治療に的する新規経皮吸収促進法及び皮
膚適用製剤を提供することを目的とする。
However, since the conventional drug injection method by jet injection is to directly make a hole in the skin and inject the drug solution,
Although it has excellent immediate effect, it is not suitable for sustainability and sustained release. Therefore, the present invention has been made in view of the above-mentioned drawbacks of the prior art, and provides a jet injection transdermal absorption device and a jet injection transdermal absorption promoting method using jet injection, which are excellent in sustainability and sustained release. To aim. Furthermore, the present invention provides a novel method for promoting percutaneous absorption and skin which are suitable for the treatment of patients who cannot orally administer or who need to maintain the internal concentration of the drug for a long period of time by increasing the percutaneous absorption or skin transferability of the drug. The purpose is to provide an applied formulation.

【0004】[0004]

【課題を解決するための手段】これまでジェットインジ
ェクションにより皮膚に形成された穴を通しての薬物経
皮吸収性あるいは薬物皮膚移行性上昇については応用さ
れた例はない。また経皮吸収製剤等があるが、皮膚に穴
をあけた上から薬剤を経皮吸収させるという考え方のも
のは知られていない。そこでジェットインジェクション
により皮膚にあけた穴から薬剤を透過させるリザバー
(容器)を貼着させることを考えたものである。皮膚透
過速度がリザバー中の溶媒の皮膚を介した流速に依存し
ているので、薬物の経皮吸収速度が予め予測できる。こ
のような吸収速度の予測の高さは従来の促進機能を有す
る皮膚適用製剤又は経皮吸収型製剤では期待できない。
ジェットインジェクション部に薬物を含むか含まない溶
液を仕込み、薬物リザバー上から皮膚に射出して、薬物
の透過ルートとなる小孔を形成し、その部位に皮膚適用
製剤を投与するという吸収促進法及び皮膚適用製剤であ
る。ここでリザバーとしては、底部と天井部に開放部を
有する箱状ケーシングと該ケーシングの底部の開放部を
閉塞する薬剤透過性の粘着剤層とケーシングの天井部開
放部を閉塞するラバーとで構成した。ラバーは、特に限
定しないが例えば医療用シリコーンゴムを使用すること
ができる。また天井部開放部を円形とし該周縁に半円球
状のラバーの接着すると良い。
[Means for Solving the Problems] Up to now, there has been no application of the drug percutaneous absorption through a hole formed in the skin by jet injection or the increase in drug skin transferability. Further, there are transdermal absorption preparations and the like, but there is no known method of percutaneously absorbing a drug after making a hole in the skin. Therefore, it is considered to attach a reservoir (container) that allows a drug to permeate through a hole formed in the skin by jet injection. Since the skin permeation rate depends on the flow rate of the solvent through the skin in the reservoir, the transdermal absorption rate of the drug can be predicted in advance. Such high prediction of absorption rate cannot be expected in the conventional dermal application preparation or transdermal absorption preparation having a promoting function.
A jet injection part is charged with a solution containing or not containing a drug, and the solution is injected from above the drug reservoir into the skin to form a small hole that serves as a drug permeation route, and a skin application formulation is administered to the site. It is a skin application preparation. Here, the reservoir is composed of a box-shaped casing having an opening at the bottom and the ceiling, a drug-permeable adhesive layer that closes the opening at the bottom of the casing, and a rubber that closes the opening at the ceiling of the casing. did. The rubber is not particularly limited, but for example, medical silicone rubber can be used. Further, it is preferable that the opening of the ceiling portion is circular and a semi-spherical rubber is adhered to the periphery.

【0005】[0005]

【作用】ジェトインジェクタから薬物リザバーを介して
皮膚に向けてジェット射出すると、皮膚表面に孔があ
く。射出に際して、リザバーのラバーの上から射出する
と、溶液の射出時に形成されるラバーの小孔は瞬時にふ
さがり、該ラバーから薬液が漏れないようになる。一方
皮膚に面した粘着剤層及び皮膚の角質層にも穴があくが
粘着剤層は粘着性を有しているために塞がれる。尚、射
出に際して薬物や溶解液の拡散はないように工夫しなけ
ればならない。
When the jet injector ejects the jet from the jet injector to the skin through the drug reservoir, the skin surface has holes. When ejecting from above the rubber of the reservoir at the time of ejection, the small holes of the rubber formed at the time of injecting the solution are instantly blocked, and the chemical solution does not leak from the rubber. On the other hand, the pressure-sensitive adhesive layer facing the skin and the stratum corneum of the skin also have holes, but the pressure-sensitive adhesive layer is closed because it has adhesiveness. At the time of injection, it must be devised so that the drug or solution does not diffuse.

【0006】ジェットインジェクションからの射出は数
回にわたって可能である。すなわち、薬物リザバー部の
ジェットインジェクション部側は、前述したようにシリ
コーンラバー等を用いることができるが、更なる吸収促
進を期待する場合などこの方法を利用できる。尚。吸収
速度は皮膚にあけた小孔の数に比例する。ラバーの部分
を半円球にすることにより、皮膚の場所を少しずらして
小孔をあけることができる。
Injection from jet injection is possible several times. That is, silicone rubber or the like can be used on the jet injection portion side of the drug reservoir portion as described above, but this method can be used when further absorption promotion is expected. still. The rate of absorption is proportional to the number of small holes in the skin. By making the rubber part a hemisphere, you can make small holes in the skin to make small holes.

【0007】本発明において、皮膚適用リザバー部に充
填薬剤の形態は特に限定されず、例えば軟膏剤、クリー
ム剤、液剤、ローション剤、リニメント剤、ゲル剤、等
の種々の形態とすることができる。吸収速度を最大限に
高めるためには液剤で、かつ表面張力が低いものが望ま
しい。
In the present invention, the form of the drug to be filled into the skin-applied reservoir is not particularly limited, and various forms such as an ointment, a cream, a liquid, a lotion, a liniment, a gel and the like can be used. . In order to maximize the absorption rate, it is desirable that the liquid agent has a low surface tension.

【0008】さらに薬物リザバー中での薬物溶解性を上
昇させるための手段としては、pHの調節剤、アルコー
ル類及びグリコール類の添加又は植物油の添加等が好ま
しい。 またジェットインジェクション部としてはプレ
ジェットの他、水圧により比較的非浸襲的に皮膚角質層
に孔を形成することが可能なものが好ましい。一般的な
注射器もこの方法に応用できる。なお、ジェットインジ
ェクション部は不要時取り外すことも可能である。
Further, as means for increasing the drug solubility in the drug reservoir, addition of pH regulators, alcohols and glycols, addition of vegetable oil and the like are preferable. In addition to the pledget, the jet injection part is preferably a part capable of relatively non-invasively forming a hole in the stratum corneum of the skin by water pressure. A general syringe can also be applied to this method. The jet injection part can be removed when not needed.

【0009】[0009]

【実施例】【Example】

実施例1 図1に示すようにその天井部に円形穴及び底部に開口を
有する箱状のケーシング1と、該天井部の円形穴の周縁
に下凸となるように接着した半球状のシリコンラバー2
と、前記底部開口を閉塞するアクリル系の粘着剤層3に
よりリザバー4を形成し、該リザバー4のシリコンラバ
ー2の上からプレシジェット(小玉薬品の商品名)5を
射出させるように構成した経皮吸収促進のための装置を
作成した。尚6は、粘着剤層を被覆するライナーであ
る。次に前記リザバー4内に30%硫酸ゲンタマイシン
水溶液を充填した。体重約200gのヘアレスラット
(WBN/ILA−Ht)を背位に固定した後に、左右
の足の固定位置を入れ替えて臀部を上に向け、前述リザ
バー4を皮膚に貼着した。このリザバー4のシリコンラ
バーの上から60μlの整理食塩水を仕込んだプレシジェ
ットを密着させ、最小圧力に調節して、液を射出した。
ラットの両足の位置を元に戻して固定した後、経時的に
採血を行い血漿中の硫酸ゲンタマイシンの量を測定し
た。結果は図2に示す通りである。硫酸ゲンタマイシン
は、FPIA法で測定した。
Example 1 As shown in FIG. 1, a box-shaped casing 1 having a circular hole in the ceiling and an opening in the bottom, and a hemispherical silicon rubber bonded to the peripheral edge of the circular hole in the ceiling so as to be downwardly convex. Two
And a reservoir 4 is formed from the acrylic adhesive layer 3 that closes the bottom opening, and a presidget (trade name of Kodama Chemical Co., Ltd.) 5 is ejected from above the silicone rubber 2 of the reservoir 4. A device for promoting skin absorption was created. In addition, 6 is a liner for coating the pressure-sensitive adhesive layer. Next, the reservoir 4 was filled with a 30% gentamicin sulfate aqueous solution. After fixing a hairless rat (WBN / ILA-Ht) having a body weight of about 200 g in the back position, the fixing positions of the left and right feet were exchanged, the buttocks were turned upward, and the reservoir 4 was attached to the skin. From above the silicone rubber of the reservoir 4, a precision jet charged with 60 μl of normalized saline was brought into close contact, adjusted to the minimum pressure, and the solution was injected.
The positions of both legs of the rat were restored and fixed, and then blood was collected over time to measure the amount of gentamicin sulfate in plasma. The results are shown in FIG. Gentamicin sulfate was measured by the FPIA method.

【0010】実施例2 同様の方法で30%硫酸ゲンタマイシン水溶液の代わり
に2%塩酸ニカルジピン/10%エタノール水溶液、1
%テオフィリン/10%エタノール水溶液又はpHを
9.3にしてテオフィリンの溶解度を上昇させた10%
のアミノフィリン水溶液をそれぞれリザバー4に充填
し、ヘアレスラット(WBN/ILA−Ht)を背位に
固定した後に、左右の足の固定位置を入れ替えて臀部を
上に向け、前述リザバー4を皮膚に貼着した。このリザ
バー4のシリコンラバーの上から60μlの整理食塩水を
仕込んだプレシジェットを密着させ、最小圧力に調節し
て、液を射出した。ラットの両足の位置を元に戻して固
定した後、経時的に採血を行い血漿中の各薬剤の量を測
定したところ、それぞれ図3、図4及び図5に示す通り
となった。尚、テオフィリン及びアミノフィリンは、F
PIA法で塩酸ニカルジピオンはHPLC法で測定し
た。いずれの薬物においても実験時間24時間にわたっ
て血中濃度の持続が認められ、また静脈注射の結果から
得られる血漿中濃度推移を用いてデコンボリューション
演算を行い、角薬物の経皮吸収速度を体積流の単位で求
めた値は、薬物種に無関係にほぼ0.42μl/hであ
った。
Example 2 In the same manner, 2% nicardipine hydrochloride / 10% ethanol aqueous solution was used instead of 30% gentamicin sulfate aqueous solution, and 1
% Theophylline / 10% aqueous ethanol solution or 10% with pH adjusted to 9.3 to increase theophylline solubility
After filling the reservoir 4 with each of the aminophylline aqueous solutions, and fixing the hairless rats (WBN / ILA-Ht) in the dorsal position, swap the fixing positions of the left and right feet and turn the buttocks upward, and apply the reservoir 4 to the skin. I wore it. From above the silicone rubber of the reservoir 4, a precision jet charged with 60 μl of normalized saline was brought into close contact, adjusted to the minimum pressure, and the solution was injected. After the positions of both legs of the rat were returned to the original position and fixed, blood was collected over time and the amount of each drug in plasma was measured. The results are as shown in FIGS. 3, 4, and 5, respectively. Theophylline and aminophylline are F
Nicardipionine hydrochloride was measured by PIA method by HPLC method. For each drug, the blood concentration was observed for 24 hours, and the deconvolution calculation was performed using the plasma concentration transition obtained from the results of intravenous injection to calculate the transdermal absorption rate of the horny drug by volume flow. The value obtained by the unit of was about 0.42 μl / h regardless of the drug species.

【0011】実験例3 実験例1と同様な方法で分子量3万の卵胞刺激ホルモン
についてもリザーバー4に充填した後にヘアレスラット
に貼着固定し、このリザバー4のシリコンラバーの上か
ら60μlの整理食塩水を仕込んだプレシジェットを密着
させ、最小圧力に調節して、液を射出した。ラットの両
足の位置を元に戻して固定した後、経皮吸収の実験を行
った。卵胞刺激ホルモンとしてはセローノジャパン社の
メトロジンを用い、750IU/mlの水溶液1mlを適用し
た。定量はセロザイムにて行った。血漿中濃度推移の結
果は図6に示す通りである。吸収速度は体積流として約
0.011μl/hである。
Experimental Example 3 In the same manner as in Experimental Example 1, a follicle-stimulating hormone having a molecular weight of 30,000 was filled in the reservoir 4 and then fixed and fixed on a hairless rat. A water-prepared precision jet was brought into close contact, adjusted to the minimum pressure, and the liquid was ejected. After returning the rats to the original positions and fixing them, transdermal absorption experiments were carried out. As follicle-stimulating hormone, Metrozine manufactured by Serono Japan Co. was used, and 1 ml of an aqueous solution of 750 IU / ml was applied. Quantification was performed with cellozyme. The results of changes in plasma concentration are shown in FIG. Absorption rate is approximately as volume flow
It is 0.011 μl / h.

【0012】[0012]

【効果】経皮吸収促進装置及び方法としての本発明は、
通常の物理的あるいは化学的促進法では経皮吸収が困難
と考えられる高分子薬物においても経皮吸収が認めら
れ、また低分子のものではその吸収速度は体積流として
ほぼ一定であるため、血中濃度の予測性に優れ、適用基
剤への薬物溶解性を上昇させることで、多くの薬物に応
用が可能である。また血漿中濃度の維持においても優れ
た持続性を示すものである。リザバー中の薬物溶解度を
50%まで上昇させることができれば現在臨床的に経口
投与されている薬物のうち、一日の常用量が5mg以下の
ものについては応用可能である。また初回通過効果によ
って前進循環系に至るまでに失活する薬物に対してはそ
れ以上の用量も応用できると解釈できる。さらに高分子
であるペプチドホルモンには極めて微量で作用するもの
が多いため、吸収速度が低くなっても、本法を用いるこ
とで経皮的に効果を得る可能性がある。
[Effect] The present invention as a device and method for promoting percutaneous absorption is
Percutaneous absorption is observed even in high molecular weight drugs that are considered to be difficult to percutaneously absorb by ordinary physical or chemical acceleration methods. It has excellent predictability of medium concentrations and can be applied to many drugs by increasing the drug solubility in the applicable base. It also shows excellent sustainability in maintaining plasma concentration. If the drug solubility in the reservoir can be increased to 50%, it is applicable to the clinically orally administered drugs which have a daily daily dose of 5 mg or less. Further, it can be construed that a higher dose can be applied to a drug that is inactivated by the first-pass effect until reaching the advanced circulatory system. Furthermore, since many peptide hormones that are macromolecules act in extremely small amounts, even if the absorption rate is low, it is possible to obtain a transdermal effect by using this method.

【図面の簡単な説明】[Brief description of drawings]

【図1】 本発明にかかる経皮吸収促進装置を示す一部
破断正面図ある。
FIG. 1 is a partially cutaway front view showing a device for promoting percutaneous absorption according to the present invention.

【図2】 実施例1の薬物の血漿中の濃度推移を示すグ
ラフである。
FIG. 2 is a graph showing changes in the concentration of the drug of Example 1 in plasma.

【図3】 実施例2の薬物(塩酸ニカルジピン酸)の血
漿中の濃度推移を示すグラフである。
FIG. 3 is a graph showing changes in the plasma concentration of the drug of Example 2 (nicardipic acid hydrochloride).

【図4】 実施例2の薬物(テオフィリン)の血漿中の
濃度推移を示すグラフである。
FIG. 4 is a graph showing changes in the concentration of the drug (theophylline) of Example 2 in plasma.

【図5】 実施例2の薬物(アミノフィリン)の血漿中
の濃度推移を示すグラフである。
FIG. 5 is a graph showing changes in the concentration of the drug (aminophylline) of Example 2 in plasma.

【図6】 実施例3の卵胞刺激ホルモンの血漿中の濃度
推移を示すグラフである。
FIG. 6 is a graph showing changes in concentration of follicle-stimulating hormone in plasma in Example 3.

【符号の説明】[Explanation of symbols]

1 ケーシング 2 シリコンラバー 3 粘着剤層 4 リザバー 5 インジェクタ(プレシジェット) 6 ライナー 1 Casing 2 Silicone rubber 3 Adhesive layer 4 Reservoir 5 Injector (Precijet) 6 Liner

【手続補正書】[Procedure amendment]

【提出日】平成6年7月28日[Submission date] July 28, 1994

【手続補正1】[Procedure Amendment 1]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】発明の名称[Name of item to be amended] Title of invention

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【発明の名称】 ジェットインジェクション経皮吸収装
置及び経皮吸収促進方法
Title: Jet injection transdermal absorption device and method for promoting transdermal absorption

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 水圧により皮膚の角質層に穴をあけるジ
ェットインジェクタと、リザバーとからなり、該リザバ
ーが底部と天井部に開放部を有する箱状ケーシングと該
ケーシングの底部の開放部を閉塞する薬剤透過性の粘着
剤層とケーシングの天井部開放部を閉塞するラバーとか
らなるジェットインジェクション経皮吸収装置。
1. A jet injector for making a hole in the stratum corneum of the skin by water pressure, and a reservoir, the reservoir closing a box-shaped casing having an opening at the bottom and the ceiling and an opening at the bottom of the casing. A jet injection percutaneous absorption device comprising a drug-permeable adhesive layer and a rubber that closes a ceiling opening portion of a casing.
【請求項2】 前記ラバーがシリコンラバーで構成さ
れ、粘着剤層を構成する粘着剤がゴム系又はアクリル系
のもので構成されていることを特徴とする請求項1記載
のジェットインジェクション経皮吸収装置。
2. The jet injection transdermal absorption according to claim 1, wherein the rubber is made of silicone rubber, and the adhesive constituting the adhesive layer is made of rubber or acrylic. apparatus.
【請求項3】 ケーシング天井部の開放部が円形の穴で
形成され、それを閉塞するラバーが半球状のもので構成
されていることを特徴とする請求項1記載のジェットイ
ンジェクション経皮吸収装置。
3. The jet injection percutaneous absorption apparatus according to claim 1, wherein the opening portion of the ceiling portion of the casing is formed by a circular hole, and the rubber that closes the opening is formed of a hemispherical shape. .
【請求項4】 薬剤吸収を望む薬剤が液状、ゲル又は乳
化状態で充填されたリザバーを皮膚に貼着する工程と、
該貼着した後に天井部に設けたラバーの上からジェット
インジェクタを皮膚に向けて射出させる工程とからなる
経皮吸収促進方法。
4. A step of applying to a skin a reservoir filled with a drug desired to be absorbed in a liquid, gel or emulsified state,
A method for promoting percutaneous absorption, which comprises a step of injecting a jet injector toward the skin from above a rubber provided on the ceiling after the sticking.
JP07934294A 1994-03-25 1994-03-25 Jet injection transdermal absorption device Expired - Fee Related JP3425469B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP07934294A JP3425469B2 (en) 1994-03-25 1994-03-25 Jet injection transdermal absorption device

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP07934294A JP3425469B2 (en) 1994-03-25 1994-03-25 Jet injection transdermal absorption device

Publications (2)

Publication Number Publication Date
JPH07255845A true JPH07255845A (en) 1995-10-09
JP3425469B2 JP3425469B2 (en) 2003-07-14

Family

ID=13687234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP07934294A Expired - Fee Related JP3425469B2 (en) 1994-03-25 1994-03-25 Jet injection transdermal absorption device

Country Status (1)

Country Link
JP (1) JP3425469B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003321350A (en) * 2002-02-28 2003-11-11 Lintec Corp Percutaneously absorbable preparation and method for percutaneously absorbing drug using the same
WO2007071485A1 (en) * 2005-12-20 2007-06-28 Novo Nordisk A/S Skin retention device for a medical jet injection unit
JP2009525094A (en) * 2006-01-31 2009-07-09 ノボ・ノルデイスク・エー/エス Pre-filled medical jet injection device seal
US7858112B2 (en) 2002-02-28 2010-12-28 Lintec Corporation Percutaneous absorption system and percutaneous absorption method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5755157A (en) * 1980-09-19 1982-04-01 Nitto Electric Ind Co Drug member having transcataneous absorbing property
JPH03151982A (en) * 1989-10-27 1991-06-28 Korea Res Inst Of Chem Technol Method and device for percutaneous administration of protain and peptide drug
JPH06504215A (en) * 1991-01-09 1994-05-19 パル スヴェードマン Percutaneous perfusion of fluids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5755157A (en) * 1980-09-19 1982-04-01 Nitto Electric Ind Co Drug member having transcataneous absorbing property
JPH03151982A (en) * 1989-10-27 1991-06-28 Korea Res Inst Of Chem Technol Method and device for percutaneous administration of protain and peptide drug
JPH06504215A (en) * 1991-01-09 1994-05-19 パル スヴェードマン Percutaneous perfusion of fluids

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003321350A (en) * 2002-02-28 2003-11-11 Lintec Corp Percutaneously absorbable preparation and method for percutaneously absorbing drug using the same
US7858112B2 (en) 2002-02-28 2010-12-28 Lintec Corporation Percutaneous absorption system and percutaneous absorption method
WO2007071485A1 (en) * 2005-12-20 2007-06-28 Novo Nordisk A/S Skin retention device for a medical jet injection unit
JP2009519798A (en) * 2005-12-20 2009-05-21 ノボ・ノルデイスク・エー/エス Skin holding device for medical jet injection unit
US8652095B2 (en) 2005-12-20 2014-02-18 Novo Nordisk A/S Skin retention device for a medical jet injection kit
JP2009525094A (en) * 2006-01-31 2009-07-09 ノボ・ノルデイスク・エー/エス Pre-filled medical jet injection device seal
US8920365B2 (en) 2006-01-31 2014-12-30 Novo Nordisk A/S Seal for a prefilled medical jet injection device

Also Published As

Publication number Publication date
JP3425469B2 (en) 2003-07-14

Similar Documents

Publication Publication Date Title
Lee et al. Bleomycin-coated microneedles for treatment of warts
RU2472539C2 (en) Methods and devices for desmopressin preparation delivery
US6908448B2 (en) Substance delivery device
CN101146523B (en) Transdermal delivery systems
US20050131359A1 (en) Substance delivery system
Ronnander et al. Transdermal delivery of sumatriptan succinate using iontophoresis and dissolving microneedles
Bala et al. Transdermal drug delivery system (TDDS)-a multifaceted approach for drug delivery
Yadav Transdermal drug delivery system
JPH08502952A (en) Transdermal administration of oxybutynin
JPH09505279A (en) Monoglyceride / lactate permeation enhancer for oxybutynin
Sugibayashi et al. Polymers for transdermal drug delivery systems
KR20020000180A (en) Device and method for increasing the transdermal permeation of medicaments
EP3572119B1 (en) Preparation of a portable transdermal administration patch apparatus
Thirunavukkarasu et al. Transdermal drug delivery systems for the effective management of type 2 diabetes mellitus: A review
Inoue et al. Fundamental investigation of a novel drug delivery system, a transdermal delivery system with jet injection
JP3425469B2 (en) Jet injection transdermal absorption device
TW592729B (en) Rate-controlled transdermal administration of risperidone
John Review on transdermal drug delivery system
Chandrasekaran et al. Therapeutic systems and controlled drug delivery
Chorghe et al. Transdermal drug delivery system: A review
Shah et al. Transdermal controlled delivery of verapamil: characterization of in vitro skin permeation
Jose et al. Recent Progress of Transdermal Drug Delivery Systems for Biomedical Applications
Yates et al. Engineering development of therapeutic systems: a new class of dosage forms for the controlled delivery of drugs
Bajpai et al. Recent Advancement on TDDS (Transdermal Drug Delivery System)
Deulkar et al. A review on transdermal drug delivery system

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090502

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100502

Year of fee payment: 7

LAPS Cancellation because of no payment of annual fees